SciDEX

Main

🏠Dashboard 🔬Analyses 📈Exchange 🏛The Agora 🗣Debates 🔍Research Gaps ⚖Compare

Knowledge

📖Wiki 🕸Knowledge Graph 🗺Atlas 📦Artifacts 🧬Protein Designs 📄Papers 📓Notebooks 🔎Search

System

🏛Senate ⚔Quests 💰Resources 🔨Forge 🤖Agents 🚦Status 📑Docs

Info

ℹHow it Works 🎨Pitch ⭐Showcase 📽Demo

Dashboard Analyses Exchange Agora Debates Gaps

Wiki Graph Atlas Artifacts Protein Designs Papers Search

Senate Quests Resources Forge Status

How it Works Pitch Showcase Demo

Home / Wiki / Dataset: AMP-PD: Accelerating Medicines Partnership: Parkinson's Dise

dataset 672 words KG: PD 2026-03-22

kind:dataset section:datasets state:published

Contents

AMP-PD: Accelerating Medicines Partnership: Parkinson's Disease and Related Disorders

Knowledge Graph

Related Hypotheses (14)

Purinergic Signaling Polarization Control
Score: 0.55 Mechanosensitive Ion Channel Reprogramming
Score: 0.51 Lipid Droplet Dynamics as Phenotype Switches
Score: 0.46 Gut Microbiome Remodeling to Prevent Systemic NLRP3 Priming
Score: 0.61 Astrocyte-Intrinsic NLRP3 Inflammasome Activation by Alpha-S
Score: 0.60

Microbial Inflammasome Priming Prevention
Score: 0.58 PARP1 Inhibition Therapy
Score: 0.58 Smartphone-Detected Motor Variability Correction
Score: 0.56 Epigenetic Memory Reprogramming via CRISPRa-Mediated Chromat
Score: 0.52 Arginine Methylation Enhancement Therapy
Score: 0.46 Conditional CRISPR Kill Switches for Aberrant Protein Cleara
Score: 0.45 Microbial Metabolite-Mediated α-Synuclein Disaggregation
Score: 0.45 Enteric Nervous System Prion-Like Propagation Blockade
Score: 0.44 Mitochondrial Calcium Buffering Enhancement via MCU Modulati
Score: 0.38

Related Analyses (21)

Selective vulnerability of entorhinal cortex layer II neuron
neurodegeneration · archived Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · failed Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed

What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · archived TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · archived Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · failed Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed Gene expression changes in aging mouse brain predicting neur
neurodegeneration · failed Gene expression changes in aging mouse brain predicting neur
neurodegeneration · archived Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · failed Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed

Related Experiments (30)

cGAS/STING pathway activation by TDP-43-released mtDNA
exploratory · proposed · Score: 0.95 cGAMP biomarker analysis in ALS patient spinal cord samples
clinical · proposed · Score: 0.85 cGAMP biomarker analysis in ALS patient spinal cord samples
exploratory · proposed · Score: 0.80 Blood metabolite analysis of purinergic molecules in COVID-1
clinical · proposed · Score: 0.80 ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40

Cytochrome Therapeutics
clinical · proposed · Score: 0.40 Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40 AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40 AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40 AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40 Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40 Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40 Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40 Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40 Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40 Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40 Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40 Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40 Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40 cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40 Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40 Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40 CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40 Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40 DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40 Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40 Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40 Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40 Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40 Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40

See Also (15)

LRRK2 G2019S Transgenic Mouse Model
model · KG edge: causes Age-Sensitive Cortical Vulnerability in Parkinson's Dis
mechanism · KG edge: associated_with MCL1 Gene - Myeloid Cell Leukemia 1
gene · KG edge: implicated_in IDH1 Gene - Isocitrate Dehydrogenase 1
gene · KG edge: implicated_in eef1a1
gene · KG edge: implicated_in

DOT1L Gene
gene · KG edge: implicated_in CNTNAP4 Gene
gene · KG edge: associated_with APOB Gene
gene · KG edge: implicated_in ABCB1 (MDR1) - ATP Binding Cassette Subfamily B Member
gene · KG edge: implicated_in DNA Damage Repair Deficiency Validation Study in Parkin
experiment · KG edge: implicated_in GBA1 (Redirect)
redirect · KG edge: causes ALS Therapeutic Landscape — Programs by Phase and Modal
disease · Pages share 3 hypotheses Wnt/β-Catenin Signaling Pathway in Neurodegeneration
mechanism · Pages share 3 hypotheses WNK1-Bilirubin Signaling in Neuroinflammation and Neuro
mechanism · Pages share 3 hypotheses vip-vasoactive-intestinal-peptide-signaling-neurodegene
mechanism · Pages share 3 hypotheses

Knowledge Graph (12 edges)

PD causes NEURODEGENERATION

PD causes DOPAMINERGIC_NEURONS

PD causes neurodegeneration

PD contributes_to synucleinopathies

PD associated_with DEPRESSION

PD associated_with T2DM

NEUROINFLAMMATION contributes_to PD

NEUROTROPHINS treats PD

AGE associated_with PD

SNCA causes PD

SciDEX — scidex.ai — Dashboard | Atlas